Objectives: To clarify the efficacy of intravesical Bacillus Calmette-Guérin (BCG) instillation for non-muscle invasive bladder (NMIBC) cancer with variant histology, especially glandular differentiation or squamous differentiation. Materials and methods: From May 1991 through June 2016, 53 patients were diagnosed retrospectively as having NMIBC with variant histology. Among these patients, 47 NMIBC patients with squamous differentiation or glandular differentiation were analyzed for this study. The median follow-up interval from diagnosis of NMIBC with variant histology was 28.9 months (1.5-168.8).
Introduction
Urothelial carcinoma (UC) is the most common histologic subtype of urinary bladder cancer. A number of histologic variants of UC have been recognized in recent years (1) . Previous studies have showed that 5-40% of cases consist of UC with variant histology or non-UC (2-11).
Variant histology is more aggressive than conventional UC. UCs with variant histology are associated with a higher grade and stage compared with conventional UC. Some reports showed that at the time of the initial diagnosis of UC with VH, 70% or more of patients had muscle invasive bladder cancer and 15-30% NMIBC (3, 5, 7, (12) (13) (14) . A pathological re-review of cystectomy specimens indicated that variant histology was associated with a high rate of locally advanced disease, which might impact the rate of survival (11) . Furthermore, NMIBC with variant histology often has a poor prognosis with an increased risk for progression. NMIBC with variant histology is considered to be a high risk condition and is recommended for early cystectomy or restaging transurethral resection of the bladder tumor (TURBT) (15) .
On the other hand, the efficacy of intravesical Bacillus CalmetteGuérin (BCG) instillation for NMIBC cancer with variant histology is unclear. There are few reports or case studies of the efficacy of BCG treatment for NMIBC patients with variant histology (16, 17) . Since the most common histological variants are squamous differentiation (SC) and glandular differentiation (GD) (3, 14) , the aim of this study was to clarify the clinical efficacy of BCG treatment for NMIBC patients with these variant histologies.
Patients and methods
Patients' characteristics (Table 1) Data from 53 consecutive patients who were diagnosed as having NMIBC with variant histology from May 1991 through June 2016 were retrospectively obtained from two institutes (Sapporo Medical University and NTT East Japan Sapporo Hospital). Among these patients, 47 NMIBC patients with GD or SC differentiation were analyzed in this study. Patients who had a history of muscle-invasive bladder cancer (MIBC) or NMIBC with different variant histology from GD and SC were excluded from this study. The pathology slides, except for those of 21 patients for whom archived slides were not available, were reviewed by two urological pathologists to examine the variant rate. The pathological grades were classed as Grade 1 (G1), Grade 2 (G2) or Grade 3 (G3) according to the 1973 WHO system. The mean follow-up interval from TURBT followed by diagnosis of NMIBC with GD or SC differentiation was 28.9 months (1.5-168.8). For all patients, pathological staging was performed according to the TNM system. Progression was defined as muscular invasion and remote and lymph node metastasis during the follow-up period. The immunotherapy protocol included an induction course of at least four or more weekly intravesical instillations of BCG. Maintenance therapy included three instillations at 3, 6 and 12 months for 1 year followed by every 6 months for an additional 2 years. Maintenance therapy and second transurethral resection of the bladder tumor (second TUR) were offered depending on the clinical doctor's selection.
Follow-up schedule
The follow-up protocol consisted of cystoscopy and urine cytology every 3 months in the first 3 years and subsequently every 6 months. In this follow-up period, if bladder cancer recurrence was suspected based on urine cytology or cystoscopy, TUR was performed to determine whether the patient was disease free. Upper urinary tract monitoring was performed with either computed tomography or an intravenous urogram. The endpoints in this study were recurrence-free survival (RFS), progression-free survival (PFS), cancer-specific survival (CSS) and overall survival (OS). The secondary endpoint in this study was cystectomy-free survival (CFS).
The study was approved by the ethics committee in our university.
Statistics
Kaplan-Meier curves were calculated for RFS, PFS, CSS, OS and CFS. RFS, PFS, CSS, OS and CFS in univariate analysis were compared between the groups using the log-rank test. Age distribution was compared using the Mann-Whitney U test. The variables sex, variant histology, recurrent tumors, tumor size and concomitant carcinoma in situ (CIS) were compared using Fischer's exact test. Multiplicity, tumor morphology and second TUR were compared using the chi-squared test. T stage, grade and the variant histology rate were compared using the Kruskal-Wallis test. Statistical tests were performed with EZR version 1.35 (EZR, Saitama Medical Center, Jichi Medical University, Saitama, Japan). Differences were considered significant if P < 0.05. (Fig. 2) . Table 2 shows predictive factors for patients with and without BCG treatment after TURBT for the 41 patients with bladder preservation therapy. The only significant difference was the proportion of those with second TUR before BCG treatment (P = 0.042).
The RFS, PFS, CSS and OS of patients with and without BCG treatment are shown in Fig. 3 . There were significant differences between BCG and other treatments or no additional treatment for recurrence (P = 0.034), progression (P = 0.004), and cancer-specific survival (P = 0.014). However, there was no significant difference in OS between the two groups (P = 0.160). We analyzed the RFS and PFS for the six patients with intravesical BCG therapy without second TUR and seven patients without intravesical BCG with second TUR. Although there was no significant difference in RFS between the two groups (P = 0.92), there was a significant difference between the patients with BCG without second TUR and without BCG with second TUR for progression (P = 0.023). The patients with intravesical BCG without second TUR had a lower incidence of progression than patients without intravesical BCG with second TUR (Supplement 1a-b) . Among the 41 patients with bladder preservation therapy, three patients with BCG treatment and three without it underwent cystectomy during the follow-up period. There was no significant difference in CFS between the two groups (P = 0.604) (Supplement 1c). Their median times to recurrence were 54.2 and 14.4 months, respectively. None of the patients with bladder preservation therapy died of bladder cancer after BCG treatment. Four of the patients without BCG treatment died of bladder cancer during the follow-up period. We analyzed the correlation between the variant histology rate and prognosis for the 24 patients whose slides were available. There were no significant difference in RFS (P = 0.257), PFS (P = 1.00), CSS (P = 1.00) or OS (P = 0.173) between patients with less than 50% and those with 50% or more rates of variant histology.
Discussion
It is well known that UCs have a variety of variant histology. From 5% to 40% consist of UC with variant histology or non-urothelial cancer (2-11). In bladder cancer with variant histology, SC and GD are the most frequent variants and they are observed in from 25% to 60% and 9% to 18% of cases, respectively (1, 3, 7, 9) . Some reports noted that 70% of patients treated with cystectomy for SC and GD were diagnosed with pT3-T4 tumors and 20% of these patients had pN+ (14, 18) . Although UC with SC, GD or both types of differentiation has higher frequencies of advanced stage disease, some patients with SC or GD are diagnosed as having primary NMIBC at TURBT. Shah et al. showed that, on initial TURBT, 31% of patients with variant histology presented with clinical T1 disease, 44% with SC and 23% with GD (3). Other reports showed that the distribution according to stage was 25% for the patients with SC and/or GD for stage pT1 (5).
The method of management for patients with NMIBC with SC and/or GD is unclear. Wasco et al. reported that the presence of mixed histologic features at TURBT was an independent predictor of extravesical disease in a multivariate logistic regression model (7). Therefore they suggested that patients with mixed histologic features at TURBT might benefit from early cystectomy. However, radical cystectomy, despite advances in urinary diversion techniques, has disadvantages such as a high complication rate (19) . Furthermore, there are few reports on the efficacy of intravesical BCG treatment for patients with NMIBC with variant histology. We found that intravesical BCG instillation for SC and/or GD histology in NMIBC led to a better prognosis with regard to PFS and CSS than other treatments. Shapur et al. compared the responses to intravesical BCG treatment of 22 patients with variant NMIBC to those of 144 patients with conventional high grade UC (16) . The 2-and 5-year PFS were 92% and 84% for patients with conventional UC compared to 81% and 63%, respectively, for patients with variant histology (P = 0.02). However there was no significant difference in CSS between the two groups. They concluded that patients with SC and/or GD histology in NMIBC could be managed with BCG treatment if the tumor was not bulky (>4 cm). Gofrit et al. compared a group of 41 patients with variant histology in NMIBC to a group of 140 patients with conventional UC treated with BCG (17) . Patients with variant histology in NMIBC treated with BCG had a 27% chance of dying from this disease within 5 years compared to a 7.5% chance for patients with conventional UC. Compared with these two reports, our results showed a better outcome and prognosis in patients with SC and/or GD histology in NMIBC treated with BCG. This might have been because our patients only had SC and/or GD histology in NMIBC and not any other variant histology. Bladder cancer with variant histology is heterogeneous with different prognoses. NMIBC with the micropapillary variant is particularly aggressive with a poor prognosis compared to other types of variant histology. Of patients with the micropapillary variant in NMIBC treated with BCG, 67% developed disease progression, including 22% who developed metastatic disease (20) . In our study, the patients only had only SC and/or GD histology and our results showed that intravesical BCG treatment could be effective for SC and/or GD histology in NMIBC.
There are some limitations in this study. First, this was a retrospective study. The most important limitation is the small number of patients with SC and/or GD histology after BCG treatment. Not all of the patients underwent maintenance BCG instillation or second TUR. Despite these limitations, we believe that our results are clinically informative and will be useful for the management of patients SC and/ or GD histology in NMIBC. However, to determine the best strategy for NMIBC with variant histology, a prospective study using a larger cohort is still needed.
Conclusions
Our results show that intravesical BCG instillation for SC and/or GD histology in NMIBC leads to a better prognosis with regard to PFS and CSS than other treatments. BCG treatment may also have a clinical benefit for variant histology in NMIBC patients. However, this was a retrospective study with a small patient population and a prospective study using a larger cohort is still needed.
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